The clinical study focuses on adult patients diagnosed with metastatic RAS G12D non-squamous non-small cell lung cancer. By targeting this specific mutation, the drug aims to offer a new first-line intervention. The primary goal of the trial is to measure progression-free survival, with secondary benchmarks including overall survival, objective response rates, and patient safety data. This latest move marks a significant shift in the company's commercial-stage oncology pipeline, which has seen its stock value surge 260% over the past year.